Prime Medicine, Inc. (PRME)
NASDAQ:PRME
Want to see PRME full AI Analyst Report?
Top Page
Prime Medicine, Inc.
(NASDAQ:PRME)
Select Model
Select Model
Rating:42Neutral
Price Target:
$3.00
▼(-21.26% Downside)
Action:Reiterated
Date:06/09/26
Overall score is pressured primarily by weak financial performance (large losses, high cash burn, and rising leverage) and a bearish technical trend (price below key moving averages with negative MACD). Modestly positive governance-related corporate events provide some support, but valuation is limited by negative earnings and no dividend.
Positive Factors
Proprietary prime editing platform
Prime Medicine’s proprietary prime editing platform represents a durable competitive advantage: a differentiated, technology-led R&D foundation that can generate multiple therapeutic programs and licensing opportunities over years. As a platform play, it supports long-term optionality across indications and can create licensing, partnership, and program-level moat if clinical validation proceeds, reducing reliance on any single product outcome.
Negative Factors
Persistent unprofitability
The company’s large operating and net losses relative to modest revenue indicate structural profitability challenges. Persistent unprofitability erodes equity, constrains reinvestment capacity, and increases reliance on external funding. Unless clinical progress converts into scalable commercial revenue, losses are likely to continue pressuring long-term financial viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary prime editing platform
Prime Medicine’s proprietary prime editing platform represents a durable competitive advantage: a differentiated, technology-led R&D foundation that can generate multiple therapeutic programs and licensing opportunities over years. As a platform play, it supports long-term optionality across indications and can create licensing, partnership, and program-level moat if clinical validation proceeds, reducing reliance on any single product outcome.
Read all positive factors
Prime Medicine, Inc. (PRME) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$501.21M
Dividend YieldN/A
Average Volume (3M)2.76M
Price to Earnings (P/E)―
Beta (1Y)2.85
Revenue Growth4.89%
EPS Growth24.20%
CountryUS
Employees214
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.27
Shares Outstanding180,617,450
10 Day Avg. Volume2,906,596
30 Day Avg. Volume2,764,106
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)4.27
Price to Sales (P/S)111.44
P/FCF Ratio-3.09
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue171.44
Enterprise Value/Gross Profit-15.83
Enterprise Value/Ebitda-3.62
Forecast
1Y Price Target
$7.80Price Target Upside104.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1
Revenue Forecast (FY)$12.93M
Prime Medicine, Inc. Business Overview & Revenue Model
Company Description
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combin...
How the Company Makes Money
Prime Medicine makes money primarily through collaboration and licensing-related revenue (e.g., upfront payments, research funding, milestone payments, and potential royalties) from partnerships that use or support its prime editing platform and/o...
Prime Medicine, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
38
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.03M | 4.63M | 2.98M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -43.68M | -2.69M | 2.98M | 0.00 | 0.00 | 0.00 |
| EBITDA | -190.90M | -195.76M | -189.75M | -186.64M | -120.55M | -165.28M |
| Net Income | -198.37M | -201.14M | -195.88M | -198.13M | -121.82M | -165.37M |
Balance Sheet | ||||||
| Total Assets | 294.73M | 342.73M | 297.51M | 193.85M | 360.31M | 301.86M |
| Cash, Cash Equivalents and Short-Term Investments | 135.50M | 177.68M | 190.44M | 121.67M | 293.92M | 269.62M |
| Total Debt | 114.51M | 116.43M | 40.79M | 13.63M | 28.75M | 10.41M |
| Total Liabilities | 218.03M | 221.87M | 144.36M | 60.78M | 44.04M | 62.30M |
| Stockholders Equity | 76.70M | 120.87M | 153.15M | 133.07M | 316.27M | 239.56M |
Cash Flow | ||||||
| Free Cash Flow | -158.74M | -167.09M | -130.16M | -174.14M | -147.92M | -38.23M |
| Operating Cash Flow | -156.42M | -162.56M | -122.86M | -165.41M | -131.83M | -34.08M |
| Investing Cash Flow | -17.63M | -108.76M | 68.46M | 18.71M | -47.10M | -73.63M |
| Financing Cash Flow | 145.91M | 151.51M | 195.88M | 655.00K | 181.49M | 269.28M |
Prime Medicine, Inc. Technical Analysis
Negative
3.81
Price Trends
3.32
Negative
3.54
Negative
3.95
Negative
Market Momentum
-0.13
Positive
43.99
Neutral
17.38
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRME, the sentiment is Negative. The current price of 3.81 is above the 20-day moving average (MA) of 3.04, above the 50-day MA of 3.32, and below the 200-day MA of 3.95, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 43.99 is Neutral, neither overbought nor oversold. The STOCH value of 17.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRME.
Prime Medicine, Inc. Risk Analysis
Prime Medicine, Inc. disclosed 80 risk factors in its most recent earnings report. Prime Medicine, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Prime Medicine, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $1.64B | -16.85 | -56.07% | ― | 3.42% | -11.04% | |
52 Neutral | $3.23B | -9.87 | -43.94% | ― | 39.04% | 29.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $331.96M | -2.11 | -43.82% | ― | ― | ― | |
44 Neutral | $1.26B | -5.11 | -45.47% | ― | -72.09% | -754.83% | |
43 Neutral | $745.82M | -3.26 | -161.87% | ― | ― | -6.15% | |
42 Neutral | $501.21M | -2.59 | -188.82% | ― | 4.89% | 24.20% |
* Healthcare Sector Average
PRME
Prime Medicine, Inc.
2.90
1.28
79.01%
IMTX
Immatics
9.43
3.29
53.58%
RLAY
Relay Therapeutics
14.96
11.90
388.89%
TSHA
Taysha Gene Therapies
5.97
3.42
134.12%
SANA
Sana Biotechnology
2.85
0.04
1.42%
UPB
Upstream Bio, Inc.
6.10
-4.21
-40.83%
Prime Medicine, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
Prime Medicine Stockholders Reaffirm Board and Auditor Choices
Positive
Jun 8, 2026
On June 5, 2026, Prime Medicine, Inc. held its annual meeting of stockholders via live webcast, with 140,384,724 shares represented, establishing a quorum out of 180,615,889 eligible shares. At the meeting, shareholders elected Michael Kelly and D...
Business Operations and StrategyExecutive/Board Changes
Prime Medicine Appoints Svetlana Makhni as New CFO
Positive
Apr 16, 2026
On April 7, 2026, Prime Medicine’s board appointed Svetlana Makhni, a veteran biotechnology and healthcare finance executive with more than two decades of investment banking and CFO experience, as Chief Financial Officer and principal financ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.